top of page

NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer

Tucson, AZ, July 23, 2021 --( NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics with the issuance of US Patent No. 10946097, “Fractionated radiotherapy and chemotherapy with an oxygen therapeutic,” describing a new method of treating cancer utilizing Company’s lead drug candidate, NanO2TM, and its administration to reverse tumor hypoxia.

Recent Posts

See All

NuvOx Pharma Announces Issuance of a New Patent

Tucson, AZ,  January 2, 2024 - NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.” Evan Unger, MD, President and CE

NuvOx Announces Contract to Support NOVEL Trial

Tucson, AZ, USA, October 31, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role,


bottom of page